0.00
前日終値:
$8.28
開ける:
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額:
$413.12M
収益:
-
当期純損益:
$-52.07M
株価収益率:
0.00
EPS:
-0.2077
ネットキャッシュフロー:
$-44.93M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
Cybin Inc Stock (CYBN) Company Profile
Compare CYBN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CYBN
Cybin Inc
|
0.00 | 413.12M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.13 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
770.79 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
771.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
322.37 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | 開始されました | Jefferies | Buy |
| 2025-03-13 | 開始されました | Guggenheim | Buy |
| 2021-11-19 | ダウングレード | Maxim Group | Buy → Hold |
Cybin Inc (CYBN) 最新ニュース
Profit Review: Can Brookfield Renewable Corporation disrupt its industry2025 Earnings Surprises & Verified Momentum Stock Alerts - baoquankhu1.vn
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors - Investing.com India
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan
Published on: 2026-02-25 04:37:15 - baoquankhu1.vn
Helus Pharma appoints former Pfizer chief medical officer to board of directors - marketscreener.com
Published on: 2026-02-24 19:40:53 - baoquankhu1.vn
Former Pfizer chief medical officer joins Helus mental health push - Stock Titan
Moving Averages: What hedge funds are buying Cybin IncJuly 2025 Short Interest & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Day Trade: What is PFBCs revenue forecastJuly 2025 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn
What are Cybin Inc.’s earnings expectationsWeekly Risk Summary & Low Volatility Stock Suggestions - mfd.ru
New Highs: What hedge funds are buying Cybin IncGap Up & Long-Term Growth Stock Strategies - baoquankhu1.vn
Cybin (Helus Pharma) Names Veteran Pharma Executive Michael Cola as CEO to Drive CNS Growth - The Globe and Mail
(CYBN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers - Finviz
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth Drivers - Yahoo Finance
Cybin stock surges after positive Phase 2a trial results for depression drug - Investing.com
Cybin Inc.Common Stock (Nasdaq:HELP) Stock Quote - The Chronicle-Journal
Helus gains on published data for psychedelic drug (HELP) - Seeking Alpha
Cybin stock surges after positive Phase 2a trial results for depression drug By Investing.com - Investing.com South Africa
Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - Investing News Network
Single-dose DMT eases major depression in trial published in Nature Medicine - Stock Titan
Breakout Watch: Is Cybin Inc stock a hidden gemJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Here's Why We're Watching Cybin's (NASDAQ:HELP) Cash Burn Situation - Yahoo Finance
Is Cybin Inc. a cyclical or defensive stockSwing Trade & Low Risk Entry Point Guides - mfd.ru
What are Cybin Inc.’s recent SEC filings showing2025 Institutional Moves & High Accuracy Trade Alerts - mfd.ru
Travel Stocks: Is Cybin Inc forming a bullish divergenceQuarterly Market Summary & High Win Rate Trade Alerts - baoquankhu1.vn
Cybin (NASDAQ:HELP) Announces Earnings Results - MarketBeat
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Investing News Network
Cybin (Helus Pharma) Posts Higher Assets, Equity and Losses in Q3 FY2026 SEC Filing - TipRanks
Helus Pharma (NASDAQ: HELP) widens loss while sharply increasing cash - Stock Titan
Published on: 2026-02-13 13:41:22 - mfd.ru
Can Cybin Inc. benefit from deglobalizationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - mfd.ru
Published on: 2026-02-12 21:19:30 - mfd.ru
Fed Meeting: Is Cybin Inc impacted by rising ratesStock Surge & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Ideas Watch: Is Cybin Inc impacted by rising rates2025 Market WrapUp & Safe Entry Trade Reports - baoquankhu1.vn
Is Cybin Inc. forming a breakout pattern2025 Trading Recap & Free Weekly Watchlist of Top Performers - mfd.ru
Will Cybin Inc. Common Shares stock benefit from sector leadershipDay Trade & Fast Entry and Exit Trade Plans - mfd.ru
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution - wahanariau.com
Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026 - marketscreener.com
New Helus Pharma CEO inherits mental health drug pipeline at key trial dates - Stock Titan
Will Helus Pharma's GAD Trial Data Calm Investor Anxiety? - RTTNews
How (CYBN) Movements Inform Risk Allocation Models - Stock Traders Daily
Bank Watch: Will Cybin Inc stock benefit from M AJuly 2025 Trends & High Win Rate Trade Tips - baoquankhu1.vn
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
Jefferies Financial Group Begins Coverage on Cybin (NASDAQ:HELP) - MarketBeat
Jefferies Initiates Coverage on Cybin With Buy Rating, CA$29.88 Price Target - marketscreener.com
Trend Recap: Does Cybin Inc stock have upside surprise potential2025 Top Gainers & Risk Controlled Stock Alerts - baoquankhu1.vn
Risk Report: Is PRCH stock technically oversoldExit Point & Smart Investment Allocation Tips - baoquankhu1.vn
Market Review: Does Cybin Inc stock have upside surprise potentialJuly 2025 Action & Reliable Entry Point Alerts - baoquankhu1.vn
Cybin Inc (CYBN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):